IA
SPRY icon

IndexIQ Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

IndexIQ Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$398K Buy
+113,499
New +$494K 0.01% 735

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

IndexIQ Advisors's SPRY Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in ARS Pharmaceuticals (SPRY) in Q1 2022: 113,499 shares worth $398K. The stake represents 0.01% of the portfolio and ranks #735 among its holdings.

70 funds tracked by Wall St. Rank hold SPRY as of Q1 2022.

  • IndexIQ Advisors held 113,499 shares of ARS Pharmaceuticals worth $398K as of Q1 2022.
  • ARS Pharmaceuticals was a new IndexIQ Advisors position in Q1 2022.
  • ARS Pharmaceuticals made up 0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #735 holding.
  • 70 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.